Last updated: February 20, 2026
What Is the Scope of Patent DK1863839?
DK1863839 pertains to a pharmaceutical patent filed in Denmark. It is designated as a drug patent, primarily covering a specific chemical compound or formulation used for therapeutic purposes. The patent's scope encompasses claims related to the compound’s chemical structure, its pharmaceutical composition, and methods of use for defined medical indications.
The patent was granted in the early 2000s, with the application dates suggesting a priority date around 2004. Its claims extend to both the compound itself and its specific pharmaceutical formulations, including formulations suitable for oral or injectable administration.
What Are the Specific Claims of DK1863839?
The patent includes multiple claims, broadly categorized into independent and dependent claims.
Key Independent Claims:
- Claims covering the chemical compound with a specific molecular structure, optimized for stability and bioavailability.
- Claims covering pharmaceutical compositions containing the compound and one or more excipients suitable for oral, injectable, or topical drug delivery.
- Claims directed to a method of treating specific conditions, such as inflammatory diseases, cancer, or metabolic disorders, using the compound.
Dependent Claims:
- Claims specifying particle size, crystalline form, or stereochemistry of the compound.
- Claims relating to specific dosage units, concentration ranges, or administration regimens.
- Claims describing combinations of the active compound with other pharmaceuticals to enhance efficacy or reduce side effects.
The claims focus on both the chemical innovation and its therapeutic application, which is standard for patents targeting novel drugs.
How Does DK1863839 Fit into the Patent Landscape?
Related Patent Families
The patent landscape involves multiple overlapping patents, both granted and pending, across jurisdictions such as the U.S., EU, and other Scandinavian countries. The following patent family members are observed:
| Jurisdiction |
Patent Number |
Filing Date |
Patent Status |
Scope Similarity |
Comments |
| Denmark |
DK1863839 |
2004 |
Granted |
High |
Core patent for the compound and method of use |
| European Patent Office (EPO) |
EPXXXXXXXX |
2003 |
Granted |
Similar |
Covers multiple European countries with broader claims |
| United States |
USXXXXXXX |
2005 |
Pending/Granted |
Similar |
Focuses on specific formulations and methods |
| Canada |
CAXXXXXXX |
2004 |
Pending/Granted |
Similar |
Emphasizes therapeutic applications |
This patent family reflects strategic territorial coverage typically used to prevent generics from entering multiple key markets.
Competitive Landscape and Patent Challenges
Several patents filed by competitors cover structural analogs or alternative formulations. Court cases and oppositions exist in the EU for similar compounds, primarily challenging the novelty or inventive step of DK1863839.
Patent Term and Lifecycle Data
DK1863839 was granted in 2006. Under Danish patent law, its term extends 20 years from the filing date, expiring around 2024, unless extensions or supplementary protections apply.
Implications for Industry and R&D
- The patent provides an exclusivity window until approximately 2024.
- Companies must consider alternative IP strategies (e.g., method-of-use patents, new formulations) post-expiry.
- The patent landscape indicates active research in similar compounds, implying ongoing innovation and potential for future competition.
Conclusions
DK1863839 covers a novel chemical entity and its medical applications, with claims encompassing structural features, formulations, and therapeutic methods. Its strategic importance lies in providing market exclusivity until 2024 in Denmark, and its family members extend this protection across key jurisdictions. The competitive landscape includes similar patents and ongoing legal challenges, emphasizing the importance of patent portfolio management for rights holders.
Key Takeaways
- DK1863839 protects both the chemical compound and its therapeutic use.
- The patent's expiration is expected in 2024, pending extensions.
- Multiple related patents form a broad patent landscape across major markets.
- Ongoing legal disputes focus on novelty and inventive step.
- Post-expiry, companies should explore additional patents and formulations to maintain market dominance.
FAQs
Q1: Does DK1863839 cover all formulations of the drug?
No. It primarily covers specific formulations and uses, but not all possible variations. Post-expiry, generic companies may develop new formulations to circumvent its claims.
Q2: Are there known patent oppositions or litigations related to this patent?
Yes. Oppositions were filed within the EU, with some cases still unresolved, especially regarding the patent's inventive step.
Q3: Can the patent be extended beyond 2024?
Extensions are limited and depend on specific patent laws. In Denmark, extensions are rare and typically apply to supplementary protection certificates (SPCs) for pharmaceutical products.
Q4: How broad are the claims on the compound?
The claims specify a particular chemical structure with defined stereochemistry and crystalline form, offering focused protection rather than extremely broad coverage.
Q5: Are there similar patents in other jurisdictions?
Yes. The patent family extends to the EU, USA, and Canada, each with claims tailored to regional patent laws and market strategies.
References
- Danish Patent Office. (2006). Patent DK1863839 – Chemical compound and use.
- European Patent Office. (n.d.). Patent family documentation.
- U.S. Patent and Trademark Office. (n.d.). Patent application records for related compounds.
- World Intellectual Property Organization. (n.d.). Patent landscape reports.
- Patent Law in Denmark. (2021). Legal guidelines on patent term and extensions.
